NJBIZ7h
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Off-brand weight loss drug makers are suing the FDA again
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
6 Stocks to Buy as European Markets Soar
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
Why Hims & Hers Health, Inc. (HIMS) Went Down on Tuesday
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
MM&M7h
What did Big Pharma CEOs get paid in 2024?
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Hosted on MSN14h
Is This Penny Stock’s 525% Upside Potential an Attainable Goal?
A smart investment strategy is to diversify your portfolio with both stable, established companies and growth stocks. Growth ...